pairingsPairing
Caution: TIGIT + PD-(L)1 blockade
Adding a TIGIT blocker to PD-1/PD-L1 blockade looked good in phase 2 and then failed repeatedly in phase 3.
SKYSCRAPER-01 (tiragolumab + atezolizumab, NSCLC), SKYSCRAPER-02 (SCLC), and others negative; Roche and others discontinued most programmes in 2024-25. Phase 2 signals did not reproduce.
Rationale
Unclear; Fc-effector requirements, patient selection, and redundancy with PD-1 are proposed explanations.
Evidence
Multiple negative phase 3.